Early results from a phase 1b trial of a new Alzheimer’s drug suggest possible benefits for people in the early stages of the disease. The antibody, known as aducanumab or BIIB037, was tested by pharmaceutical company Biogen, with results presented today at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Nice, France.
Phase 1 Alzheimer’s trial results show potential benefits
Leave a reply